Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label MDMA-assisted psychotherapy for severe PTSD
NL-OMON27176Phase 2Not yet recruiting
- Sponsor
- Kuypers Pharma Consulting
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Kuypers Pharma Consulting. Primary endpoint: Change in CAPS-5 Total Severity Score. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON27176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27176.